BTG3 and interstitial lung disease: ILD guidelines recommend routine serological testing in all patients with newly identified ILD, including for anti-nuclear antibodies (ANA) by immunofluorescence, with onward referral to rheumatology, if there are extra-pulmonary connective tissue disease (CTD) features or positive serologies (25).